AbCellera Biologics Inc. ABCL PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept abcl:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsAfterAccumulatedDepreciationAndAmortization.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s PP&E (net)?
- AbCellera Biologics Inc. (ABCL) reported PP&E (net) of $422.81M in Q1 2026.
- How has AbCellera Biologics Inc.'s PP&E (net) changed year-over-year?
- AbCellera Biologics Inc.'s PP&E (net) increased by 21.8% year-over-year, from $347.1M to $422.81M.
- What is the long-term trend for AbCellera Biologics Inc.'s PP&E (net)?
- Over 3 years (2022 to 2025), AbCellera Biologics Inc.'s PP&E (net) has grown at a 25.4% compound annual growth rate (CAGR), from $217.26M to $428M.
- What does PP&E (net) mean?
- This represents the net book value of long-term tangible assets, such as laboratory equipment, facilities, and infrastructure, required to support the company's research and development operations. It reflects the capital intensity of the business model and the investment made in the physical capacity necessary to execute antibody discovery programs. Changes in this balance indicate the company's ongoing commitment to expanding or maintaining its technical capabilities.